Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an update.
At the annual general meeting of Alligator Bioscience AB held on May 7, 2025, several key resolutions were adopted. The company decided to carry forward an accumulated loss of SEK 127,127,801 without paying dividends. The board members and CEO were discharged from liability for the financial year 2024. Hans-Peter Ostler was elected as the new Chairman of the board, and Öhrlings PricewaterhouseCoopers AB was re-elected as the auditor. Additionally, the board was authorized to issue new shares, convertibles, and warrants to raise working capital and expand strategic ownership.
More about Alligator Bioscience AB
Alligator Bioscience AB operates in the biotechnology industry, focusing on the development of innovative antibody-based therapies for cancer treatment.
Average Trading Volume: 186,782
Current Market Cap: SEK67.62M
For an in-depth examination of ATORX stock, go to TipRanks’ Stock Analysis page.